Table 2 Clinico-pathological parameters and SHOX2 and SEPT9 methylation levels prior to treatment
Clinico-pathological parameters | Total number (n) | Methylation in plasma prior to treatment | ||||
|---|---|---|---|---|---|---|
Number (n) | Median SEPT9 (%); IQR | Spearman’s ρ, P-valuea | Median SHOX2 (%); IQR | Spearman’s ρ, P-valuea | ||
All CRC cases | 184 (100%) | 155 (100%) | ||||
Localisation | ||||||
Caecum | 34 (18.5%) | 33 (21.3%) | 0.061; 0.37 | 0.072; 0.19 | ||
Ascending colon | 33 (17.9%) | 30 (19.4%) | 0.031; 0.25 | 0.036; 0.15 | ||
Transverse colon | 13 (7.1%) | 8 (5.2%) | 0.009; 0.08 | 0.009; 0.05 | ||
Descending colon | 10 (5.4%) | 9 (5.8%) | 0.155; 21.87 | 0.013; 7.99 | ||
Sigmoid colon | 44 (23.9%) | 39 (25.2%) | 0.055; 0.47 | 0.033; 0.12 | ||
Rectum | 43 (23.4%) | 30 (19.4%) | 0.161; 0.74 | P = 0.52 | 0.068; 0.25 | P = 0.40 |
Othersc | 7 (3.8%) | 6 (3.9%) | 0.616; 2.99 | 0.156; 0.35 | ||
Primary tumour (T) category | ||||||
Tis | 1 (0.5%) | 0 (0.0%) | N/A | N/A | ||
T1 | 14 (7.6%) | 8 (5.2%) | 0.000; 0.01 | 0.029; 0.10 | ||
T2 | 30 (16.3%) | 27 (17.4%) | 0.016; 0.19 | 0.014; 0.09 | ||
T3 | 103 (56.0%) | 92 (59.3%) | 0.123; 0.65 | ρ = 0.28 | 0.044; 0.21 | ρ = 0.25 |
T4 | 30 (16.3%) | 24 (15.5%) | 0.188; 0.80 | P < 0.001 | 0.131; 0.21 | P = 0.002 |
N/Ab | 6 (3.3%) | 4 (2.6%) | 0.413;0.58 | 0.023; 0.07 | ||
Regional node (N) category | ||||||
N0 | 97 (52.7%) | 89 (57.4%) | 0.037; 0.25 | 0.032; 0.10 | ||
N1 | 41 (22.3%) | 36 (23.2%) | 0.150; 0.59 | ρ = 0.28 | 0.071; 0.27 | ρ = 0.29 |
N2 | 27 (14.7%) | 25 (16.1%) | 0.393; 4.22 | P = 0.001 | 0.171; 1.16 | P < 0.001 |
Nx | 19 (10.3%) | 5 (3.2%) | 0.109; 0.63 | 0.000; 0.05 | ||
Distant metastasis (M) category | ||||||
M0 | 159 (86.4%) | 132 (85.2%) | 0.049; 0.28 | 0.037; 0.14 | ||
M1a | 18 (9.8%) | 16 (10.3%) | 2.231; 4.18 | 0.296; 1.36 | ||
M1b | 7 (3.8%) | 7 (4.5%) | 0.393; 10.64 | P < 0.001 | 0.121; 1.25 | P = 0.001 |
Histopathological grade | ||||||
G1 | 9 (4.9%) | 9 (5.8%) | 0.000; 0.10 | 0.017; 0.05 | ||
G2 | 134 (72.8%) | 117 (75.5%) | 0.055; 0.35 | ρ = 0.32 | 0.049; 0.14 | ρ = 0.26 |
G3 | 28 (15.2%) | 23 (14.8%) | 0.661; 4.45 | P < 0.001 | 0.184; 1.28 | P = 0.001 |
N/Ab | 13 (7.1%) | 6 (3.9%) | 0.074; 28.79 | 0.164; 13.89 | ||
Lymphatic invasion (L) | ||||||
L0 | 121 (65.8%) | 102 (65.8%) | 0.041; 0.25 | 0.037; 0.12 | ||
L1 | 53 (28.8%) | 46 (29.7%) | 0.215; 1.12 | P = 0.005 | 0.092; 0.29 | P = 0.033 |
N/Ab | 10 (5.4%) | 7 (4.5%) | 0.319; 24.01 | 0.228; 10.30 | ||
Vascular invasion (V) | ||||||
V0 | 158 (85.9%) | 134 (86.5%) | 0.071; 0.53 | 0.043; 0.16 | ||
V1 | 13 (7.1%) | 11 (7.1%) | 0.184; 0.39 | P = 0.86 | 0.079; 0.18 | P = 0.20 |
N/Ab | 13 (7.1%) | 10 (6.4%) | 0.090; 7.39 | 0.050; 3.18 | ||
Surgical margin (R) | ||||||
R0 | 175 (95.1%) | 148 (95.5%) | 0.071; 0.47 | 0.049; 0.16 | ||
R1 | 6 (3.3%) | 4 (2.6%) | 0.214; 1.61 | P = 0.66 | 0.126; 0.74 | P = 0.38 |
R2 | 0 (0.0%) | 0 (0.0%) | N/A | N/A | ||
N/Ab | 3 (1.6%) | 3 (1.9%) | 24.036; N/A | 10.301; N/A | ||
UICC stage | ||||||
I | 37 (20.1%) | 29 (18.7%) | 0.000; 0.04 | 0.008; 0.08 | ||
II | 64 (34.8%) | 58 (37.4%) | 0.083; 0.31 | 0.034; 0.16 | ||
III | 48 (26.1%) | 43 (27.7%) | 0.125; 0.56 | ρ = 0.41 | 0.078; 0.22 | ρ = 0.32 |
IV | 25 (13.6%) | 23 (14.8%) | 1.845; 4.34 | P < 0.001 | 0.171; 1.25 | P < 0.001 |
N/Ab | 10 (5.4%) | 2 (1.3%) | 0.104; N/A | 0.023; N/A | ||
Extracapsular lymph node extension (ece) | ||||||
ece−/N0 | 129 (70.1%) | 106 (68.4%) | 0.041; 0.25 | 0.034; 0.13 | ||
ece+ | 31 (16.8%) | 26 (16.8%) | 0.606; 3.24 | 0.143; 0.48 | ||
N/Ab | 24 (13.0%) | 23 (14.8%) | 0.180; 1.82 | P = 0.001 | 0.049; 0.80 | P = 0.016 |
